Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/104692ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF
WO 27.05.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2020/130409 Applicant BLISS BIOPHARMACEUTICAL (HANGZHOU) CO., LTD. Inventor XIA, Bing
An isolated IgG antibody includes two identical heavy chains each having a hinge region with an amino acid sequence containing an additional cysteine upstream of the two cysteines in the CPPCP sequence of a native IgG hinge region, and a CH1 domain containing a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs based on the antibody having this architecture are also provided.
2.WO/2022/106057TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES
WO 27.05.2022
Int.Class A61K 8/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
64Proteins; Peptides; Derivatives or degradation products thereof
Appl.No PCT/EP2021/025445 Applicant THE BOOTS COMPANY PLC Inventor BELL, Michael, David
According to the present invention there is provided a tetrapeptide, capable of inducing dermal extracellular matrix protein upregulation, selected from the group consisting of tetrapeptides having the amino acid sequence U-QTAV-Z wherein Q is used to denote amino acid Glutamine, T is used to denote amino acid Threonine, A is used to denote amino acid Alanine and V is used to denote amino acid Valine, at the N- terminal end, U is independently selected from the group consisting of octanoyl (C8), decanoyl (C10), lauroyl (C12), myristoyl (C14), palmitoyl (C16), stearoyl (C18), biotinoyl, elaidoyl, oleoyle, lipoyle, at the C-terminal end, Z is selected from the group consisting of OH, O R1, NHR1 or NR1 R2, R1 and R2 are independently selected from the group consisting of alkyl, aryl, aralkyl, alkylaryl, alkoxy, saccharide and aryloxy group, which may be linear, branched, cyclical, polycyclic, unsaturated, hydroxylates, carbonylated, phosphorylated and/or sulphurous, said groups comprising from 1 to 24 carbon atoms and being capable of including one or more heteroatoms O, S and/or N.
3.WO/2022/105922SSX2 ANTIGEN DERIVED SHORT PEPTIDES
WO 27.05.2022
Int.Class C07K 7/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Appl.No PCT/CN2021/132192 Applicant XLIFESC, LTD. Inventor LI, Yi
The present invention relates to SSX2 antigen derived short peptides, and in particular to SSX2 derived tumor antigen short peptides, complexes formed by the short peptides and MHC molecules, and uses of the short peptides and complexes. In addition, the present invention also relates to molecules bound to the short peptides or complexes described above, and uses of the molecules.
4.WO/2022/107737SARS-CoV-2 DETECTION KIT AND SARS-CoV-2 DETECTION METHOD
WO 27.05.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/JP2021/041983 Applicant FUJIFILM CORPORATION Inventor UJIHARA Dai
The present invention addresses the problem of providing a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method that enable the detection of SARS-CoV-2 in a simple manner and with higher sensitivity. The present invention provides a SARS-CoV-2 detection kit for specifically detecting a nucleocapsid protein (NP) contained in a biological sample, the SARS-CoV-2 detection kit comprising at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), wherein the antibody includes at least one antibody of which the subclass is IgG2b, and the kit includes a first container that receives a silver-containing compound, and a second container that receives a reducing agent that can reduce silver ions.
5.WO/2022/105772BISPECIFIC ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST CORONAVIRUS, AND USE THEREOF
WO 27.05.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2021/131080 Applicant SANYOU BIOPHARMACEUTICALS CO., LTD. Inventor LANG, Guojun
Provided are a bispecific antibody having a neutralizing activity against a coronavirus, and a use thereof. A neutralizing antibody which is against a coronavirus S protein and blocks the binding of the coronavirus S proteins to an ACE 2 receptor is provided to prevent and treat coronaviruses. Specifically provided is an antibody or polypeptide complex specifically binding to a coronavirus S protein, comprising: (a) a first epitope binding moiety comprising a heavy chain variable region VH and a light chain variable region VL, wherein the VH and VL form an antigen binding domain specifically binding to a first epitope of an S protein; and (b) a second epitope binding moiety comprising a single-domain antibody or a VHH fragment thereof specifically binding to a second epitope of the S protein, wherein the first and second epitope binding portions are fused to each other and are not identical to each other. Also provided is a polynucleotide for encoding an antibody or a polypeptide complex and a host cell comprising same, and a method for preparing an antibody or a polypeptide complex. The antibody or polypeptide complex can be used for preventing, treating, diagnosing, and/or detecting coronaviruses.
6.WO/2022/105787LONG ACTING BI-SPECIFIC T CELL ENGAGERS TARGETING CD3 AND CD47
WO 27.05.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/CN2021/131181 Applicant SHENZHEN ENDURING BIOTECH, LTD. Inventor WEN, Yu
Provided are bispecific molecules and, in particular, long acting bispecific T cell engagers targeting CD3 and CD47 with improved efficacy, toxic profile and therapeutic window, and methods of making and using such long acting bispecific binding molecules.
7.WO/2022/105817BI-FUNCTIONAL MOLECULES
WO 27.05.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2021/131389 Applicant SUZHOU TRANSCENTA THERAPEUTICS CO., LTD. Inventor QIAN, Xueming
Provided are proteins comprising a PD- L1-binding moiety linked to a TGFβ-binding moiety, IL-1-binding moiety, immunostimulatory polypeptides (e.g., soluble LAG3 or soluble CD4) or CD47-binding moiety, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same and the uses thereof.
8.WO/2022/105832ANTI-PD-L1 NANOBODY AND TRIFUNCTIONAL FUSION PROTEIN
WO 27.05.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/131479 Applicant QURE BIOTECHNOLOGY (SHANGHAI) CO., LTD. Inventor QU, Xiangdong
The present invention relates to an anti-PD-L1 nanobody and a trifunctional fusion protein. The anti-PD-L1 nanobody and an Fc fusion protein thereof are strong in specificity, high in affinity, and weak in immunogenicity in humans, and has a remarkable anti-tumor effect. The trifunctional fusion protein comprises a TGF-β inhibitor, a VEGF inhibitor and a PD-L1 inhibiting antibody, and has a very high affinity for both a human VEGF protein and a TGF-β protein and also a good affinity for a human PD-L1 protein; moreover, the trifunctional fusion protein can also block the binding of the human PD-1/PD-L1 protein.
9.WO/2022/105847LONG-ACTING NERVE GROWTH FACTOR POLYPEPTIDES AND USES THEREOF
WO 27.05.2022
Int.Class C07K 14/48
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
48Nerve growth factor (NGF)
Appl.No PCT/CN2021/131614 Applicant STAIDSON (BEIJING) BIOPHARMACEUTICALS CO. , LTD. Inventor LI, Ping
Provided are long-acting nerve growth factor (NGF) polypeptides comprising from N-terminus to C-terminus an NGF moiety and an Fc moiety, methods of making, and uses thereof.
10.WO/2022/106852POLYMER FOR PURIFICATION OF BIOMOLECULES
WO 27.05.2022
Int.Class C07K 1/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
14Extraction; Separation; Purification
Appl.No PCT/GB2021/053021 Applicant PURIUS LTD Inventor ROSE, Michael Harry
There is disclosed a composition comprising a first construct, wherein the first construct comprises a charge component, a lock component and a key component; wherein the lock component and the key component are specific affinity binding partners and are separated such that they are unable to form a binding pair within the same construct; whereby in a first environmental condition, the charge component imparts a first overall charge to the first construct, the lock component binds to its binding partner on a second construct, and the key component binds to its binding partner on a third construct; and whereby in a second environmental condition, the charge component imparts a second overall charge to the first construct, and the lock and key components are in an unbound state. Also disclosed is a method of purification of a target compound involving the composition.